Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Inclusion Criteria: * Male and female between 18 and 65 years. * Non-responders in previous treatments with IFNα plus ribavirin or pegylated IFNα plus ribavirin. * Elevated ALT-levels on at least two occasions during \>6 months preceding entry. * Detection of HCV RNA in serum (PCR). * Compensated liver disease (Child-Pugh A) and a Child-Pugh score \<5. * The following minimal hematologic and biochemical criteria: * Hemoglobin for males and females \>11g/dl * Absolute Neutrophil count \>1500 cells/mm3 * Platelets \>75'000/mm3 * HBs Ag negative. * ANA \<1:320, and no evidence for autoimmune hepatitis. * α-Fetoprotein \<50μg/l (when between upper limit of normal and 50μg/l, ultrasonographical exclusion of hepatocellular carcinoma (HCC) is needed). * Fasting blood glucose within normal limits, if history of diabetes or hypertension, a pre-therapy ocular examination is indicated. * TSH within normal limits or adequately controlled. * Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 2-3 week period prior to the first dose of study drug. Additionally, all fertile males and females must be using effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state. * Willingness to give written informed consent and willingness to participate to and comply with the study Exclusion Criteria: * Women with ongoing pregnancy or breast feeding. * Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBe Ag. * Positive test at screening for HIV. * History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures). * Hypersensitivity to study drugs. * Participation in any other clinical trial within 30 days of entry into this protocol. * Treatment with any investigational drug within 30 days of entry into this protocol. * History or evidence of decompensated liver disease (Child-Pugh B/C) and a Child-Pugh score \>5. Ascites, coagulopathy, hyperbilirubinemia, hepatic encephalopathy, or hypoalbuminemia and a Child-Pugh score \>5 are conditions consistent with decompensated liver disease. * History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease. * Hepatocellular carcinoma (HCC) or α-Fetoprotein \>50μg/l. * Patients with organ transplants other than cornea and hair transplant. * Therapy with any antisystemic or immunomodulatory treatment (including supra-physiologic doses of steroids or radiation) \<6 months prior the first dose of study drug * Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis. * Any known preexisting medical condition that could interfere with the patient's participation in and completion of the study such as: * Preexisting psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychosis, suicidal ideation and/or suicidal attempts (based on a mandatory psychiatric advice). * CNS trauma or active seizure disorders requiring medication. * Significant cardiovascular dysfunction. * Poorly controlled diabetes mellitus. * Renal dysfunction, i.e. serum creatinine levels \>1.5 times upper limit of normal. * Autoimmune diseases. * Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration). * Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids. * Clinical gout. * Important substance abuse (alcohol \>80 g/d, i.v. drugs etc.). * Active opportunistic infections. * Non-Hodgkin lymphoma or Hodgkin lymphoma. * Kaposi sarcoma. * Inability or unwillingness to provide informed consent or abide by the requirements of the study. * Male partners of pregnant women.